European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.
View/ Open
Date
2014-02-01ICR Author
Author
Engelhardt, M
Terpos, E
Kleber, M
Gay, F
Wäsch, R
Morgan, G
Cavo, M
van de Donk, N
Beilhack, A
Bruno, B
Johnsen, HE
Hajek, R
Driessen, C
Ludwig, H
Beksac, M
Boccadoro, M
Straka, C
Brighen, S
Gramatzki, M
Larocca, A
Lokhorst, H
Magarotto, V
Morabito, F
Dimopoulos, MA
Einsele, H
Sonneveld, P
Palumbo, A
European Myeloma Network,
Type
Journal Article
Metadata
Show full item recordAbstract
Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B).
Collections
Subject
European Myeloma Network
Multiple Myeloma
Antineoplastic Combined Chemotherapy Protocols
Hematopoietic Stem Cell Transplantation
Clinical Trials, Phase III as Topic
Autografts
Research team
Molecular Haematology (including Cytogenetics Group and Cell Markers)
Language
eng
License start date
2014-02
Citation
Haematologica, 2014, 99 (2), pp. 232 - 242
Publisher
FERRATA STORTI FOUNDATION
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.
Coulson, AB; Royle, K-L; Pawlyn, C; Cairns, DA; Hockaday, A; et al. (BMJ PUBLISHING GROUP, 2022-06-02)INTRODUCTION: Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this ... -
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
(2008-03)The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches ... -
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS).
Messiou, C; Hillengass, J; Delorme, S; Lecouvet, FE; Moulopoulos, LA; et al. (RADIOLOGICAL SOC NORTH AMERICA, 2019-04-01)Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific ...